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SHORT COMMUNICATION
A novel BRD4-NUT fusion in an undifferentiated sinonasal
tumor highlights alternative splicing as a contributing
oncogenic factor in NUT midline carcinoma
A Stirnweiss1, K McCarthy2, J Oommen1, ML Crook3, K Hardy4, UR Kees1, SD Wilton5, A Anazodo2,6 and AH Beesley1
NUT midline carcinoma (NMC) is a fatal cancer that arises in various tissues along the upper midline of the body. The deﬁning
molecular feature of NMC is a chromosomal translocation that joins (in the majority of cases) the nuclear testis gene NUT (NUTM1)
to the bromodomain protein family member 4 (BRD4) and thereby creating a fusion oncogene that disrupts cellular differentiation
and drives the disease. In this study, we report the case of an adolescent NMC patient presenting with severe facial pain, proptosis
and visual impairment due to a mass arising from the ethmoid sinus that invaded the right orbit and frontal lobe. Treatment
involved radical resection, including exenteration of the affected eye with the view to consolidate treatment with radiation therapy;
however, the patient experienced rapid tumor progression and passed away 79 days post resection. Molecular analysis of the
tumor tissue identiﬁed a novel in-frame BRD4-NUT transcript, with BRD4 exon 15 fused to the last 124 nucleotides of NUT exon 2
(BRD4-NUT ex15:ex2Δnt1–585). The partial deletion of NUT exon 2 was attributed to a mid-exonic genomic breakpoint and the
subsequent activation of a cryptic splice site further downstream within the exon. Inhibition of the canonical 3′ acceptor splice site
of NUT intron 1 in cell lines expressing the most common NMC fusion transcripts (PER-403, BRD4-NUT ex11:ex2; PER-624, BRD4-NUT
ex15:ex2) induced alternative splicing from the same cryptic splice site as identiﬁed in the patient. Detection of low levels of an
in-frame BRD4-NUT ex11:ex2Δnt1–585 transcript in PER-403 conﬁrmed endogenous splicing from this alternative exon 2 splice site.
Although further studies are necessary to assess the clinical relevance of the increasing number of variant fusions described in NMC,
the ﬁndings presented in this case identify alternative splicing as a mechanism that contributes to this pathogenic complexity.
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INTRODUCTION
NUT midline carcinoma (NMC) is a particularly aggressive and fatal
form of undifferentiated epithelial cancer affecting both children
and adults.1 The genetic hallmark of this disease is a rearrange-
ment of chromosome 15 - in the majority of cases fusing the
testis-speciﬁc nuclear gene NUT (also known as NUTM1 and
C15orf55) to the bromodomain-containing gene BRD4 (bromodo-
main protein family member 4) on chromosome 19 and thereby
creating a new fusion protein that markedly disrupts squamous
cell differentiation and promotes oncogenesis.2–4 Variant fusions
between NUT and the bromodomain protein BRD3, or the nuclear
receptor SET domain-containing protein NSD3 have also been
described.5–7 Currently, little is known about the functionality of
NUT beside its association with the histone acetyltransferase p300,
which is thought to contribute to postmeiotic histone hyperace-
tylation and chromatin compaction in elongating spermatids.2 In
contrast, BRD4 is an important member of the bromodomain and
extra-terminal domain proteins (the BET family) known to regulate
cell cycle progression, survival signaling, chromatin structure,
epigenetic memory and embryonic stem cell development.8–11
This ubiquitously expressed transcriptional coactivator contains
two bromodomains that enable BRD4 to recognize and bind
epigenetic marks on DNA, and a domain at the C terminus that
recruits the positive transcription elongation factor b (P-TEFb)
and is thus critical for the assembly of the transcriptional
machinery.8,10,12 Exactly how the fusion of those two proteins
alters their biological function in the context of NMC however, is
still not fully understood.
RESULTS AND DISCUSSION
A 14-year-old girl presented to a local emergency department
with severe right facial pain and visual disturbance. On examina-
tion there was altered sensation over the right cheek, diplopia,
ptosis, proptosis and signiﬁcant visual impairment of the right eye.
Magnetic resonance imaging (MRI) and computed tomography
(CT) scans demonstrated an irregular destructive mass involving
the superior nasal cavity, the right anterior ethmoid and right
maxilla, extending through the medial wall of the right orbit,
compressing and invading the medial rectus with pressure effect
and displacement of the optic nerve. Additionally, the cribiform
plate was destroyed and there was involvement in the right
frontal lobe (Figures 1a and b). There was no evidence of distant
metastasis on positron emission tomography or abdominal and
1Division of Children’s Leukaemia and Cancer Research, Telethon Kids Institute, The University of Western Australia, West Perth, WA, Australia; 2Kids Cancer Centre, Sydney
Children’s Hospital, Randwick, NSW, Australia; 3Department of Pathology, Princess Margaret Hospital for Children, Perth, WA, Australia; 4Cyto Labs Pty Ltd, Perth, WA, Australia;
5Molecular Therapy Laboratory, Western Australian Neuroscience Research Institute, Centre for Comparative Genomics, Murdoch University, Perth, WA, Australia and 6Prince of
Wales Hospital, Randwick, NSW, Australia. Correspondence: Professor AH Beesley, Division of Children’s Leukaemia and Cancer Research, Telethon Kids Institute, The University of
Western Australia, PO Box 855, West Perth, WA 6872, Australia.
E-mail: alex.beesley@telethonkids.org.au
Received 4 September 2015; accepted 22 September 2015
Citation: Oncogenesis (2015) 4, e174; doi:10.1038/oncsis.2015.33
www.nature.com/oncsis
chest CT scans (data not shown). Detailed histological examination
of a biopsy specimen identiﬁed an undifferentiated tumor with
high nuclear:cytoplasmic ratio and a high mitotic rate, arranged in
nests with abrupt squamous differentiation (Figure 1c, upper
panel). Further immunohistochemistry provided no evidence for
the presence of neuroendocrine differentiation markers (data not
shown) but revealed positive staining for NUT (Figure 1c, lower
panel). Fluorescence in situ hybridization showed a separation of
probes targeted proximal and distal to the NUT gene (Figure 1e),
conﬁrming the diagnosis of NMC. The rapid diagnosis allowed
enrollment on and consultation with the International NMC
Registry at the Dana-Farber Cancer Institute, providing access to
a current data set that was used to guide treatment. Forty-one
days after the patient underwent radical resection including
exenteration of the affected eye, she re-presented with signiﬁ-
cantly increased facial pain, swelling, clear rhinorrhea and
impairment of vision in the left eye. CT imaging showed disease
progression within the surgical site, nasal cavity and ethmoid sinus
with extension into the anterior cranial fossa and into the left
orbit, impinging upon the left optic nerve (Figure 1d). Access to
experimental BET inhibitor treatment was unfortunately not
possible owing to legislative, geographical and ﬁnancial issues,
as well as limitations of clinical trial design - problems that are not
uncommon in the wider Australian adolescent and young adult
cancer population.
The patient passed away 98 days after her original biopsy.
Cytogenetic analysis of viable cells from a post-mortem sample
revealed a t(15;19)(q14;p13.13) rearrangement consistent with the
presence of a BRD4-NUT fusion (Figure 2b). RNA analysis via
reverse transcriptase PCR (RT–PCR) identiﬁed the transcript fusion
position to be downstream from BRD4 exon 15 and upstream of
NUT exon 3. However, the RT–PCR product was 600 bp shorter
than that ampliﬁed from an NMC cell line that expresses a BRD4-
NUT ex15:ex2 fusion transcript (PER-624; Figure 2c). Subsequent
Sanger sequencing of the RT–PCR product conﬁrmed that the
patient-derived tumor cells expressed a novel in-frame BRD4-NUT
fusion transcript with the last 124 nucleotides (nt) of NUT exon 2
fused to BRD4 exon 15 (BRD4-NUT ex15:ex2Δnt1–585; Figure 2d). This
is the ﬁrst report of an NMC case where the BRD4-NUT transcript
does not contain the entire sequence of NUT exon 2. At the
protein level, this leads to a disruption of the proline-rich domain
NUT_N (amino acids (aa) 8–332) while the previously described
Figure 1. Case report of an adolescent diagnosed with NMC. (a) CT and (b) MRI imaging at presentation showed a mass in the superior nasal
cavity, the right anterior ethmoid and the right anterior frontal lobe, further extending through the medial wall to the right orbit and into the
right maxilla. (c) Histopathology of a diagnostic biopsy specimen. (Upper panel) Hematoxylin and eosin staining showed characteristics of
undifferentiated carcinoma with nests of abrupt squamous differentiation. (Lower panel) Immunohistochemistry staining with a NUT-speciﬁc
antibody (C52B1; Cell Signaling Technology, Boston, MA, USA). (d) CT images obtained 41 days after radical resection of the original tumor
showed disease progression within the surgical site, nasal cavity and ethmoid sinus with extension into the anterior cranial fossa and into the
left orbit impinging upon the left optic nerve. (e) Fluorescence in situ hybridization with BAC clones binding chromosome 15q14 upstream
(RP11-74D7, RP11-88A04 and RP-11-242K3 labeled with SpectrumGreen Vysis; Abbott Molecular, Des Plaines, IL, USA) and downstream (RP-11-
1H8 and RP11-477L8 labeled with Spectrum Orange Vysis; Abbott Molecular) of the NUT gene conﬁrmed the diagnosis of NMC.
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p300-binding domain (aa 346–593) remains intact.13 The fusion
protein should thus retain its ability to sequester the histone
acetyltransferase p300 - a central activity of the fusion protein that
results in foci of chromatin hyperacetylation and impaired
transcription of genes driving differentiation.4,6,14 Indeed,
immunohistochemistry of the tumor demonstrated the punctate
nuclear staining of the fusion protein that is characteristic for NMC
(Figure 1c, lower panel).
The partial deletion of NUT exon 2 within the fusion transcript
indicated the potential activation of a cryptic splice site within this
exon. In silico analysis of NUT exon 2 and 100 bp of the ﬂanking
introns using the online tool ESEﬁnder 3.0 (see Cartegni et al.15)
predicted 11 potential splice sites, including the canonical NUT
intron 1 acceptor splice site, and an internal cryptic splice site that
corresponds with the position of the fusion transcript breakpoint
in the described NMC case (Table 1). To test whether the upstream
canonical acceptor site may have been deleted as part of the
translocation event, we used nested PCR primers to amplify the
genomic region between BRD4 exon 15 and NUT exon 3. Sanger
sequencing of this product demonstrated the genomic breakpoint
Figure 2. Identiﬁcation of a novel BRD4-NUT fusion transcript. (a,b) Cytogenetic analysis of a biopsy specimen obtained at diagnosis. Images
show representative metaphases of (a) normal and (b) tumor cells. (c) RT–PCR using primers targeted to BRD4 exon 15, and NUT exon 3 (see
Supplementary Table 2) identiﬁed an approximately 600 bp shorter BRD4-NUT product in the patient sample compared with that of the cell
line PER-624, which is known to expresses a BRD4-NUT ex15:ex2 fusion transcript. Methods: Total RNA was extracted in TRIzol (Life
Technologies, Carlsbad, CA, USA), puriﬁed using the RNeasy Mini Kit (Qiagen, Valencia, CA, USA) and reverse transcribed using the SuperScript
VILO cDNA Synthesis Kit (Life Technologies). PCR products were ampliﬁed using GoTaq Flexi DNA polymerase (Promega, Madison, WI, USA)
and puriﬁed with the QIAquick Gel Extraction Kit (Qiagen). (d) Sanger sequencing of the RT–PCR product ampliﬁed from patient-derived RNA
identiﬁed a unique transcript with BRD4 exon 15 fused to the last 124 nucleotides of NUT exon 2 (i.e., with deletion of the ﬁrst 585 nucleotides
of exon 2).
Table 1. Potential splice sites within NUT exon 2 and 100 bp of the adjacent introns predicted by ESEﬁnder 3.0
Nta Motif Sequence (5′–3′) Score
− 15 3′ acceptor splice siteb tctttgtctcaacagCATCTGCATTGCCGG 9.20
85 3′ acceptor splice site CTTCTGACCCACCAGACCACCCACCCAGGG 8.92
142 3′ acceptor splice site CAGTATTCTCTCCAGACAACCCTCTGATGC 7.74
173 3′ acceptor splice site CTCTGCTTTCCCCAGCTCACTGTTGGTGAC 11.11
231 5′ donor splice site GCTGGGGCTGGCAAGGTCATTGTCAAAGTC 5.79
260 5′ donor splice site CAAGACAGAAGGGGGGTCAGCTGAGCCCTC 5.24
303 3′ acceptor splice site TTTATCCTTACTCAGACTGCCCTCAATTCG 8.08
408 3′ acceptor splice site ATTCTGCCCTCTAAGGCTGTTGGTGTCAGC 6.67
453 3′ acceptor splice site GGCCTTCCGCCTCAGCCTCCACCACCAGTT 7.50
571 5′ donor splice site CCAAGCCTTCCCTAGGTGACCGCTCCAAAA 6.21
571 3′ acceptor splice sitec CCAAGCCTTCCCTAGGTGACCGCTCCAAAA 6.98
695 5′ donor splice siteb TTCCTGTTTTCTTATGTAAGTGGGGAGACC 5.48
Abbreviation: Nt, nucleotide. aNt positions relative to the start of NUT exon 2, intronic sequences are in lowercase and exonic sequences in uppercase.
bCanonical splice site. cCryptic splice site that has been activated in the index case.
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to also be within NUT exon 2 but 70 bp upstream from the RNA
breakpoint (Figure 3). Hence, the genomic breakpoint within NUT
is mid-exonic and results in the deletion of all predicted acceptor
splice sites in NUT exon 2 except for the implicated cryptic site
(Table 1). Even though use of this cryptic splice site has not been
reported before, RNA splicing is known to have a key role in
generating NMC fusion transcripts; at a chromosome level, NUT
exon 1 is intact in all other fusion genes so far described and its
removal via splicing is therefore essential to maintain an open
reading frame.3,16 Importantly, the use of the cryptic splice site
within NUT exon 2 maintains this open reading frame, whereas
complete removal of exon 2 (and thus direct fusion of BRD4 to
NUT exon 3) would result in premature truncation of the transcript.
To further examine the role of NUT exon 2 splicing in NMC, we
generated antisense oligomers (AOs) to block predicted splice
sites (Table 1) and exonic splicing enhancers (Supplementary
Table 1). We analyzed the effects of seven different AOs
(Figure 4a) in two cell lines that represent the most common
BRD4-NUT variants in NMC (PER-403, ex11:ex2; PER-624, ex15:
ex2).3,17 In both cases, only AO no. 1, targeting the canonical NUT
intron 1/exon 2 acceptor site, induced alternative splicing
(Figures 4b and c). Sanger sequencing of the corresponding
RT–PCR products from both cell lines identiﬁed transcripts missing
the ﬁrst 585 nt of NUT exon 2 (PER-403, BRD4-NUT ex11:ex2Δnt1–585;
PER-624, BRD4-NUT ex15:ex2Δnt1–585), thus conﬁrming the activa-
tion of the same cryptic 3′ acceptor splice site observed in the
index case. Although different BRD4 exons are involved, the
resulting fusions in both cell lines remain in frame. We did not
observe any changes in phenotype in either cell line correlated
with this splicing switch, in terms of growth rate or differentiation
status (Ki67 or cytokeratin staining), consistent with the clinical
observation that the NUT ex2Δnt1–585 fusion variant remains highly
oncogenic (i.e. the patient succumbed to disease 98 days after
diagnosis). Furthermore, low endogenous levels of BRD4-NUT
ex11:ex2Δnt1–585 fusion transcript were detected in PER-403
(Figure 4c, lipofectamine and mock control lanes; breakpoint
conﬁrmed by sequencing), indicating that use of the cryptic splice
site in NUT exon 2 may occur naturally in other NMC cases. Over
the past decade, it has become evident that alteration of normal
splicing patterns in tumors can support the progression to a more
aggressive phenotype. The functions promoted by cancer-speciﬁc
isoforms range from antiapoptotic and proproliferative (e.g., EGFR,
BCL-Xs, BRAF), to angiogenic (VEGF-A), hyperenergetic (PKM, LDHC),
immune modulative (HLA-G, MHC-I) and prometastatic (TGF-β,
CDH1, FGFR2).18 The expression of multiple fusion isoforms within
NMC could therefore have important implications for tumor
phenotype as well as the design of targeted therapies.
For more than 20 years, the predominant oncogenic variant in
NMC was thought to involve the fusion of BRD4 exon 11 to the
start of NUT exon 2. Only recently, two additional BRD4-NUT
isoforms have been described (BRD4-NUT ex14:ex2 and ex15:ex2),
which could potentially indicate the existence of clinically relevant
NMC subtypes.3,19 In this study of an adolescent NMC patient
presenting with an undifferentiated sinonasal tumor, we identify a
fourth BRD4-NUT fusion variant (BRD4-NUT ex15:ex2Δnt1–585). This
is the ﬁrst described case with a partial deletion of NUT exon 2,
which disrupts a proline-rich protein domain but without
ameliorating oncogenicity. NMC is an extremely aggressive
disease that is refractory to conventional treatments, yet
signiﬁcant preclinical and clinical responses have been reported
for BET inhibitors and histone deacetylase inhibitors, making them
promising candidates for NMC therapy.2,13,20,21 As a result of these
ﬁndings, phase I clinical trials have been opened that investigate
Figure 3. Schematic representation of the genomic rearrangements
in the index case. Genomic breakpoints (dashed lines and indicated
sequences) are located ~ 1 kb downstream from the end of BRD4
exon 15 and 515 bp downstream from the start of NUT exon 2,
resulting in the depletion of the canonical 3′ acceptor splice site of
NUT intron 1 (asterisk). Arrows illustrate the position of the
corresponding RNA breakpoints. Alternative nucleotides within the
indicated DNA sequence (e.g., C/T) indicate heterogeneity at that
position. Methods: Genomic breakpoints were ampliﬁed by nested
PCR using LongAmp DNA polymerase (New England BioLabs Inc.,
Ipswich, MA, USA) and the primer pairs are described in
Supplementary Table 2. The PCR product was puriﬁed using the
QIAquick Gel Extraction Kit (Qiagen) and analyzed via Sanger
sequencing.
Figure 4. Functional evaluation of in silico predicted splice sites in
NUT exon 2. (a) Illustration of AO binding sites, not drawn to scale.
The AOs were synthesized as 2′-O-methyl modiﬁed bases on a
phosphorothioate backbone26 and designed to target splice sites
and enhancer elements of NUT exon 2; AO sequences are described
in Supplementary Table 2. (b,c) Inactivation of the canonical
acceptor splice site (AO no. 1; lane 3) leads to a deletion of the
ﬁrst 585 nucleotides of NUT exon 2 (conﬁrmed by Sanger
sequencing). Arrows indicate the size of the corresponding
alternative splicing products. AOs were introduced into two NMC
cell lines (b) PER-624 and (c) PER-403 (representative of different
BRD4-NUT fusion variants) to manipulate normal splicing. Methods:
Cells were seeded 24 h before their transfection with 100 nM AO
using the Lipofectamine RNAiMAX Reagent (Life Technologies)
according to the manufacturer's protocol. Untreated cells (mock;
lane 1) and cells treated with Lipofectamine alone (lipo only; lane 2)
were used as controls. RNA was extracted from each of the samples
and converted into cDNA as described in Figure 3. The sequence
between BRD4 exon 15 and NUT exon 3 was ampliﬁed using the
GoTaq Flexi DNA polymerase (Promega) system and the primers
described in Supplementary Table 2.
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the efﬁcacy of different BET inhibitors (GSK525762, TEN-010,
OTX015) and a dual phosphoinositide 3 kinase/histone deacety-
lase inhibitor (CUDC-907) in NMC and other advanced cancers.
It will be some time before the results of these trials are known;
however, there is evidence that molecular factors such as the
dependency of the tumor on MYC signaling22–24 are likely to affect
the efﬁcacy of BET inhibitors in different cancer settings. Indeed,
we have previously reported that the cytotoxicity of the BET
inhibitor JQ1 may differ substantially between NMC subtypes,25
although it should be noted that observation was limited to a
small number of cell lines and did not examine the effects of this
drug class on cellular differentiation. The relationship between the
efﬁcacy of BET inhibitors and the genetic features of NMC (e.g.,
fusion type and co-operating mutations), its molecular features
(e.g., MYC expression), or its cell of origin, has not yet been
described, hence there is a continued need for a better under-
standing of the cellular processes altered by NUT fusion proteins
to develop optimal treatment strategies for NMC patients.
CONFLICT OF INTEREST
The authors declare no conﬂict of interest.
ACKNOWLEDGEMENTS
We thank both the patient and her parents for permission to use clinical information
and biological samples for ongoing research. We further thank Dr Helen Doyle and
the entire pathology team of SEALS, Prince of Wales Hospital, Randwick, NSW,
Australia for their exemplary support, Joanne Peverall (PathWest Department of
Diagnostic Genomics, Sir Charles Gairdner Hospital, WA) for the ﬂuorescence in situ
hybridization performed as part of the patient’s diagnosis, as well as Dr Adrian
Charles for interpreting the NUT IHC and his support in reviewing the ﬂuorescence
in situ hybridization results. This work was supported by the Children’s Leukaemia
and Cancer Research Foundation (CLCRF) and the Raine Medical Research
Foundation.
REFERENCES
1 French C. NUT midline carcinoma. Nat Rev Cancer 2014; 14: 149–150.
2 French CA. Pathogenesis of NUT midline carcinoma. Annu Rev Pathol 2012; 7:
247–265.
3 Thompson-Wicking K, Francis RW, Stirnweiss A, Ferrari E, Welch MD, Baker E et al.
Novel BRD4-NUT fusion isoforms increase the pathogenic complexity in NUT
midline carcinoma. Oncogene 2013; 32: 4664–4674.
4 Alekseyenko AA, Walsh EM, Wang X, Grayson AR, Hsi PT, Kharchenko PV et al. The
oncogenic BRD4-NUT chromatin regulator drives aberrant transcription within
large topological domains. Genes Dev 2015; 29: 1507–1523.
5 French CA, Ramirez CL, Kolmakova J, Hickman TT, Cameron MJ, Thyne ME et al.
BRD-NUT oncoproteins: a family of closely related nuclear proteins that block
epithelial differentiation and maintain the growth of carcinoma cells. Oncogene
2008; 27: 2237–2242.
6 Wang R, You J. Mechanistic analysis of the role of bromodomain-containing
protein 4 (BRD4) in the BRD4-NUT oncoprotein induced transcriptional activation.
J Biol Chem 2014; 290: 2744–2758.
7 Suzuki S, Kurabe N, Ohnishi I, Yasuda K, Aoshima Y, Naito M et al. NSD3-NUT-
expressing midline carcinoma of the lung: ﬁrst characterization of primary
cancer tissue. Pathol Res Pract 2015; 211: 404–408.
8 Belkina AC, Denis GV. BET domain co-regulators in obesity, inﬂammation
and cancer. Nat Rev Cancer 2012; 12: 465–477.
9 Wu SY, Lee AY, Lai HT, Zhang H, Chiang CM. Phospho switch triggers brd4
chromatin binding and activator recruitment for gene-speciﬁc targeting. Mol Cell
2013; 49: 843–857.
10 Prinjha RK, Witherington J, Lee K. Place your BETs: the therapeutic potential of
bromodomains. Trends Pharmacol Sci 2012; 33: 146–153.
11 Alsarraj J, Walker RC, Webster JD, Geiger TR, Crawford NP, Simpson RM et al.
Deletion of the proline-rich region of the murine metastasis susceptibility
gene Brd4 promotes epithelial-to-mesenchymal transition- and stem cell-like
conversion. Cancer Res 2011; 71: 3121–3131.
12 Dawson MA, Prinjha RK, Dittmann A, Giotopoulos G, Bantscheff M, Chan WI et al.
Inhibition of BET recruitment to chromatin as an effective treatment for
MLL-fusion leukaemia. Nature 2011; 478: 529–533.
13 Reynoird N, Schwartz BE, Delvecchio M, Sadoul K, Meyers D, Mukherjee C et al.
Oncogenesis by sequestration of CBP/p300 in transcriptionally inactive hyper-
acetylated chromatin domains. EMBO J 2010; 29: 2943–2952.
14 Schwartz BE, Hofer MD, Lemieux ME, Bauer DE, Cameron MJ, West NH et al.
Differentiation of NUT midline carcinoma by epigenomic reprogramming. Cancer
Res 2011; 71: 2686–2696.
15 Cartegni L, Wang J, Zhu Z, Zhang MQ, Krainer AR. ESEﬁnder: a web resource to
identify exonic splicing enhancers. Nucleic Acids Res 2003; 31: 3568–3571.
16 Haruki N, Kawaguchi KS, Eichenberger S, Massion PP, Gonzalez A, Gazdar AF et al.
Cloned fusion product from a rare t(15;19)(q13.2;p13.1) inhibit S phase in vitro.
J Med Genet 2005; 42: 558–564.
17 Kees UR, Mulcahy MT, Willoughby ML. Intrathoracic carcinoma in an 11-year-old
girl showing a translocation t(15;19). Am J Pediatr Hematol Oncol 1991; 13:
459–464.
18 Oltean S, Bates DO. Hallmarks of alternative splicing in cancer. Oncogene 2014; 33:
5311–5318.
19 Wang R, Liu W, Helfer CM, Bradner JE, Hornick JL, Janicki SM et al. Activation of
SOX2 expression by BRD4-NUT oncogenic fusion drives neoplastic transformation
in NUT midline carcinoma. Cancer Res 2014; 74: 3332–3343.
20 Maher OM, Christensen AM, Yedururi S, Bell D, Tarek N. Histone deacetylase
inhibitor for NUT midline carcinoma. Pediatr Blood Cancer 2015; 62: 715–717.
21 Grayson AR, Walsh EM, Cameron MJ, Godec J, Ashworth T, Ambrose JM et al.
MYC, a downstream target of BRD-NUT, is necessary and sufﬁcient for the
blockade of differentiation in NUT midline carcinoma. Oncogene 2013; 33:
1736–1742.
22 Mertz JA, Conery AR, Bryant BM, Sandy P, Balasubramanian S, Mele DA et al.
Targeting MYC dependence in cancer by inhibiting BET bromodomains. Proc Natl
Acad Sci USA 2011; 108: 16669–16674.
23 Da Costa D, Agathanggelou A, Perry T, Weston V, Petermann E, Zlatanou A et al.
BET inhibition as a single or combined therapeutic approach in primary
paediatric B-precursor acute lymphoblastic leukaemia. Blood Cancer J 2013;
3: e126.
24 Fowler T, Ghatak P, Price DH, Conaway R, Conaway J, Chiang CM et al. Regulation
of MYC expression and differential JQ1 sensitivity in cancer cells. PLoS ONE 2014;
9: e87003.
25 Beesley AH, Stirnweiss A, Ferrari E, Endersby R, Howlett M, Failes TW et al.
Comparative drug screening in NUT midline carcinoma. Br J Cancer 2014; 110:
1189–1198.
26 van Deutekom JC, Janson AA, Ginjaar IB, Frankhuizen WS, Aartsma-Rus A,
Bremmer-Bout M et al. Local dystrophin restoration with antisense
oligonucleotide PRO051. N Engl J Med 2007; 357: 2677–2686.
Oncogenesis is an open-access journal published by Nature Publishing
Group. This work is licensed under a Creative Commons Attribution 4.0
International License. The images or other third partymaterial in this article are included
in the article’s Creative Commons license, unless indicated otherwise in the credit line; if
the material is not included under the Creative Commons license, users will need to
obtain permission from the license holder to reproduce the material. To view a copy of
this license, visit http://creativecommons.org/licenses/by/4.0/
Supplementary Information accompanies this paper on the Oncogenesis website (http://www.nature.com/oncsis)
Alternative splicing in NUT midline carcinoma
A Stirnweiss et al
5
Oncogenesis (2015), 1 – 5
